## External Validation: Clinical Features

| Feature | Cluster 1 | Cluster 2 | Cluster 3 | P-value | Significance |
|---------|-----------|-----------|-----------|---------|--------------|
| Age at Diagnosis (years) | 61.2 ± 13.5 | 69.4 ± 12.7 | 67.1 ± 12.3 | 8.23e-05 | *** |
| Gender (% Male) | 51.5 | 50.0 | 55.3 | 0.540 | ns |
| Stage I (%) | 7.4 | 21.2 | 18.5 | 0.0065 | ** |
| Stage II (%) | 37.9 | 43.9 | 38.7 | 0.0065 | ** |
| Stage III (%) | 29.5 | 28.8 | 31.9 | 0.0065 | ** |
| Stage IV (%) | 25.3 | 6.1 | 10.9 | 0.0065 | ** |

*Statistical significance: ns = not significant, \*p<0.05, \*\*p<0.01, \*\*\*p<0.001*

**Key Findings:**
- Cluster 1 patients are significantly younger (mean 61.2 years)
- Cluster 1 has highest Stage IV rate (25.3%) — more aggressive disease
- Cluster 2 has lowest Stage IV (6.1%) — better prognosis
- Gender is balanced across clusters (not significant)
